Department of Nephrology, Changzheng Hospital, the Second Military Medical University, Shanghai, 20003, China.
Department of Nephrology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200080, China.
Curr Med Sci. 2020 Apr;40(2):327-331. doi: 10.1007/s11596-020-2179-z. Epub 2020 Apr 26.
This study compared Sheng Xue Ning (SXN) tablets with ferrous succinate (FS) tablets in terms of their efficacy for the treatment of iron-deficient renal anemia and safety in patients subject to maintenance hemodialysis (MHD). A total of 94 patients undergoing MHD were randomly assigned to an experiment group (receiving oral SXN tablets, SXN group) and a control group (orally given FS tablets, FS group) and followed up for 12 weeks. Erythropoietin (EPO) was used in both groups. The efficacy was assessed by detecting the subsequent changes in hemoglobin (Hb), serum iron (SI), SF and transferrin saturation (TSAT). At the 12th week, Hb and TSAT levels in both groups were significantly increased compared to those in the screening period (P<0.05). However, no significant difference in Hb and TSAT was found between the two groups. The average weekly EPO dosage used was lower in SXN group than in FS group (P<0.05) at the 10th week and the 12th week. Our study showed that SXN tablets can effectively ameliorate renal anemia and keep iron metabolism stable in MHD patients, and its efficacy is virtually close to that of FS tablets. Meanwhile, SXN tablets can reduce the dosage of EPO and have a good safety profile.
本研究比较了生血宁片（SXN）和琥珀酸亚铁（FS）片在治疗维持性血液透析（MHD）患者缺铁性肾性贫血的疗效和安全性。94 例 MHD 患者随机分为实验组（口服 SXN 片，SXN 组）和对照组（口服 FS 片，FS 组），随访 12 周。两组均使用促红细胞生成素（EPO）。通过检测血红蛋白（Hb）、血清铁（SI）、SF 和转铁蛋白饱和度（TSAT）的后续变化来评估疗效。第 12 周时，两组的 Hb 和 TSAT 水平均较筛选期显著升高（P<0.05）。然而，两组间 Hb 和 TSAT 无显著差异。第 10 周和第 12 周时，SXN 组的平均每周 EPO 用量均低于 FS 组（P<0.05）。本研究表明，生血宁片能有效改善 MHD 患者的肾性贫血，维持铁代谢稳定，其疗效与 FS 片相当。同时，生血宁片可减少 EPO 用量，安全性良好。
